Details for New Drug Application (NDA): 062376
✉ Email this page to a colleague
NDA 062376 describes ULTRACEF, which is a drug marketed by Bristol and Apothecon and is included in four NDAs. Additional details are available on the ULTRACEF profile page.
The generic ingredient in ULTRACEF is cefadroxil/cefadroxil hemihydrate. Twenty-two suppliers are listed for this compound. Additional details are available on the cefadroxil/cefadroxil hemihydrate profile page.
The generic ingredient in ULTRACEF is cefadroxil/cefadroxil hemihydrate. Twenty-two suppliers are listed for this compound. Additional details are available on the cefadroxil/cefadroxil hemihydrate profile page.
Summary for 062376
| Tradename: | ULTRACEF |
| Applicant: | Bristol |
| Ingredient: | cefadroxil/cefadroxil hemihydrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | EQ 125MG BASE/5ML | ||||
| Approval Date: | Mar 16, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | EQ 250MG BASE/5ML | ||||
| Approval Date: | Mar 16, 1982 | TE: | RLD: | No | |||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | EQ 500MG BASE/5ML | ||||
| Approval Date: | Mar 16, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
